Rexahn's (RNN) Supinoxin (RX-5902) has so far shown to be "safe and well-tolerated" in an ongoing Phase I trial of patients with solid cancer tumors, with no drug-related side-effects reported.
A fourth dosing cycle has been initiated following the completion of three cycles.
In animal testing, treatment with Supinoxin resulted in a significant reduction in tumor growth.
Shares jump 14.9%. (PR)